Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

These included two CpGs with higher methylation in DKD that overlapped with predicted binding sites for the transcription factor Pax-3 (cg05165263 in IRF2) and the Vitamin D3 receptor (cg10072464 between GRHL1-KLF11; Supplementary Table 4).

Source: Potential overlaps of differentially methylated CpGs with transcription factors. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Review / evidence synthesis.

Review / evidence synthesis

Reviews existing research; the exact review methods need further assessment.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Review / evidence synthesis · Nature Communications · 2022

Original publication title

Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Laura J. Smyth; Emma H. Dahlström; Anna Syreeni; Katie Kerr; Jill Kilner; Ross Doyle; Eoin Brennan; Viji Nair; Damian Fermin; Robert G. Nelson; Helen C. Looker; Christopher Wooster; Darrell Andrews; Kerry Anderson; Gareth J. McKay; Joanne B. Cole; Rany M. Salem; Peter J. Conlon; Matthias Kretzler; Joel N. Hirschhorn; Denise Sadlier; Catherine Godson; Jose C. Florez; GENIE consortium; Carol Forsblom; Alexander P. Maxwell; Per-Henrik Groop; Niina Sandholm; Amy Jayne McKnight

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Type 1 diabetes affects over nine million individuals globally, with approximately 40% developing diabetic kidney disease. Emerging evidence suggests that epigenetic alterations, such as DNA methylation, are involved in diabetic kidney disease. Here we assess differences in blood-derived genome-wide DNA methylation associated with diabetic kidney disease in 1304 carefully characterised individuals with type 1 diabetes and known renal status from two cohorts in the United Kingdom-Republic of Ireland and Finland. In the meta-analysis, we identify 32 differentially methylated CpGs in diabetic kidney disease in type 1 diabetes, 18 of which are located within genes differentially expressed in kidneys or correlated with pathological traits in diabetic kidney disease.

We show that methylation at 21 of the 32 CpGs predict the development of kidney failure, extending the knowledge and potentially identifying individuals at greater risk for diabetic kidney disease in type 1 diabetes.

Approximately 40 percent of people with type 1 diabetes develop kidney disease, but the risk factors are not well understood. Here, the authors identify DNA methylation signatures associated with diabetic kidney disease, of which 21 biomarkers predict the development of kidney failure.

Authors’ abstract

Type 1 diabetes affects over nine million individuals globally, with approximately 40% developing diabetic kidney disease. Emerging evidence suggests that epigenetic alterations, such as DNA methylation, are involved in diabetic kidney disease. Here we assess differences in blood-derived genome-wide DNA methylation associated with diabetic kidney disease in 1304 carefully characterised individuals with type 1 diabetes and known renal status from two cohorts in the United Kingdom-Republic of Ireland and Finland. In the meta-analysis, we identify 32 differentially methylated CpGs in diabetic kidney disease in type 1 diabetes, 18 of which are located within genes differentially expressed in kidneys or correlated with pathological traits in diabetic kidney disease.

We show that methylation at 21 of the 32 CpGs predict the development of kidney failure, extending the knowledge and potentially identifying individuals at greater risk for diabetic kidney disease in type 1 diabetes.

Approximately 40 percent of people with type 1 diabetes develop kidney disease, but the risk factors are not well understood. Here, the authors identify DNA methylation signatures associated with diabetic kidney disease, of which 21 biomarkers predict the development of kidney failure.

Publication and source details

Original title: Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Laura J. Smyth; Emma H. Dahlström; Anna Syreeni; Katie Kerr; Jill Kilner; Ross Doyle; Eoin Brennan; Viji Nair; Damian Fermin; Robert G. Nelson; Helen C. Looker; Christopher Wooster; Darrell Andrews; Kerry Anderson; Gareth J. McKay; Joanne B. Cole; Rany M. Salem; Peter J. Conlon; Matthias Kretzler; Joel N. Hirschhorn; Denise Sadlier; Catherine Godson; Jose C. Florez; GENIE consortium; Carol Forsblom; Alexander P. Maxwell; Per-Henrik Groop; Niina Sandholm; Amy Jayne McKnight

Nature Communications · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.The GEnetics of Nephropathy an International Effort (GENIE) is supported through the Medical Research Council (MC_PC_15025), Public Health Agency R&D Division (STL/4760/13), Science Foundation Ireland (SFI15/US/B3130), NIH R01_DK081923 and R01_DK105154.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T21:23:16.349658+00:00

DOI: 10.1038/s41467-022-34963-6 · PMC9780337